Target intelligence / Profile preview

STPG2 antisense RNA 1 (non-protein coding) (STPG2-AS1)

Target
STPG2-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA, Non-protein coding RNA, Natural antisense transcript (NAT)
01

Overview

STPG2 antisense RNA 1 (STPG2-AS1) is a long non-coding RNA (lncRNA) classified as a natural antisense transcript (NAT) that overlaps with and is transcribed from the opposite DNA strand of the STPG2 gene locus and does not encode a protein[4][5]. Like other antisense RNAs, it functions primarily in the regulation of gene expression, potentially by mechanisms such as transcriptional interference, chromatin remodeling, and epigenetic modification—common attributes of NATs[1][3]. There is currently no evidence in the biomedical literature or curated databases that STPG2-AS1 itself is a well-characterized therapeutic target, protein, enzyme, transporter, or receptor, nor are there any drugs known to directly interact with it[4][5]. No disease associations or roles have been robustly documented for STPG2-AS1 specifically as of the latest gene records[4][5]. Key context: - STPG2-AS1 is a non-coding transcript, part of the molecular family of long non-coding RNAs that regulate gene expression at transcriptional and possibly post-transcriptional levels[1][3][4]. - Antisense RNAs can impact gene expression in cis (locally) or trans (at distant sites), and can modulate chromatin state, recruit protein complexes, or regulate splicing[1][3]. - GeneCards and NCBI gene entries confirm that STPG2-AS1 is annotated in the human genome but do not link it to specific biological pathways, diseases, or pharmacological agents[4][5]. If more specific functional or disease-association data are published in future research, those would need to be reviewed for accurate classification of its biological and therapeutic relevance.

Other names
STPG2-AS1STPG2 antisense RNA 1STPG2 antisense RNA 1 (non-protein coding)
02

Biological functions

Regulation of gene expressionTranscriptional interferenceEpigenetic regulationPotential involvement in alternative splicing (inferred from general antisense RNA mechanisms[1][3])

Beyond the preview

Go deeper on STPG2 antisense RNA 1 (non-protein coding) (STPG2-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on STPG2 antisense RNA 1 (non-protein coding) (STPG2-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call